International Myeloma Society Workshop on Assessment of Response and Progression Criteria in Multiple Myeloma 2024

Name: International Myeloma Society Workshop on Assessment of Response and Progression Criteria in Multiple Myeloma 2024 - DrMedciene
SKU: MED-AMB-00620
Price: 40.00 USD
Availability: InStock

$40.00

This Product is shared via google drive download link, So please share your correct Gmail id while placing the order .Please note that there are no CME points or certificate associated with this course Samples for Courses Can be found here : Free Samples Here!

Include: 9 videos, size: 4.04 GB

SKU: MED-AMB-00620 Categories: Hematology / Oncology, Internal Medicine Tags: Internal Medicine, ONCOLOGY-HEMATOLOGY

Description
Additional information

International Myeloma Society Workshop on Assessment of Response and Progression Criteria in Multiple Myeloma 2024

Include: 9 videos, size: 4.04 GB

Target Audience: hematologists & oncologists

Information:

According to Leanne Richardson’s LinkedIn post, the IMS IMWG Multiple Myeloma Response Criteria Workshop took place in Paris in November 2024. The event focused on discussing and establishing new consensus criteria for clinical trials in multiple myeloma.

Although publicly available sources do not provide specific details about this workshop, previous workshops of the International Multiple Myeloma Working Group (IMWG) have made important contributions to standardizing response and progression criteria in the treatment of multiple myeloma. For example, international consensus response criteria for multiple myeloma were published at previous workshops, aiming to improve reporting and comparison of results between different clinical trials.
Nature

For the most up-to-date and detailed information about the conference in Paris in November 2024, you should visit the official website of the International Multiple Myeloma Society (IMS) or contact them directly.

Hematologists & Oncologists – Specialists involved in diagnosing and treating multiple myeloma.
Clinical Researchers & Scientists – Those working on new treatment strategies and response criteria for multiple myeloma.
Pharmaceutical & Biotech Industry Representatives – Companies developing new therapies and clinical trials.
Regulatory Experts & Policymakers – Authorities involved in approving and standardizing response criteria in clinical trials.
Medical Professionals & Fellows – Doctors and researchers looking to update their knowledge of response assessment in myeloma.

Topics: